Johnson & Johnson enters a Phase III clinical trial for its potential vaccine, becoming the fourth vaccine company backed by Operation Warp Speed to do so. The trial is expected to enroll up to 60,000 volunteers across 215 locations in the United States and other countries.
Johnson & Johnson enters phase III clinic trail for their potential vaccine, becoming the fourth vaccine company backed by Operation Warp Speed to do so. The trial is expected to enroll up to 60,000 volunteers across 215 locations in the United States and other countries.
Johnson & Johnson enters aPhase III clinical trial for their potential vaccine, becoming the fourth vaccine company backed by Operation Warp Speed to do so. The trial is expected to enroll up to 60,000 volunteers across 215 locations in the United States and other countries.
Johnson & Johnson enters a Phase III clinical trial for its potential vaccine, becoming the fourth vaccine company backed by Operation Warp Speed to do so. The trial is expected to enroll up to 60,000 volunteers across 215 locations in the United States and other countries.